BGM Group Ltd Dossier
Qualitative Analysis
Business overview
BGM Group Ltd. (formerly known as Qilian International Holding Group Limited before rebranding in October 2024) is a diversified healthcare and technology holding company based in Chengdu, China. Historically, the company operated primarily as a pharmaceutical and chemical manufacturer, producing active pharmaceutical ingredients (APIs) such as oxytetracycline, traditional Chinese medicine derivatives (TCMD) like Gan Di Xin and licorice preparations, crude heparin sodium, and organic fertilizers. Since late 2024, BGM has embarked on an aggressive strategic pivot toward artificial intelligence (AI) applications, intelligent robotics, algorithmic computing power, and cloud computing. This transition was accelerated by the landmark acquisition of AIX Inc.'s intelligent platform assets (including RONS Intelligent Technology and Shenzhen Xinbao Investment Management) in exchange for Class A ordinary shares, making AIX the majority shareholder and integrating the DuXiaoBao AI insurance platform into BGM's core ecosystem.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from a traditional biopharmaceutical and chemical manufacturer into an AI-integrated technology enterprise. The company is leveraging its acquired AIX intelligent platform, including the DuXiaoBao and Bao Wang platforms, to provide AI solutions and intelligent robot services for insurance companies, brokers, and consumers.
Expected impact: Diversification of revenue streams, entry into high-growth technology sectors, and optimization of traditional business lines through AI-assisted decision-making.
Integrating traditional Chinese medicine and biotechnology with premium tea resources. Following the acquisition of Wonder Dragon Global Limited, BGM plans to develop health-focused tea products (such as ginseng and goji berry Qingzhuan dark tea) and optimize tea production efficiency using its AI-powered decision-making platform.
Expected impact: Expansion of the healthcare product portfolio, enhancement of R&D capabilities in active ingredients for medicinal applications, and diversification of the product ecosystem.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire a prominent AI agent production platform and its subsidiaries (Beijing Shuda Technology and New Media Star Technology). This acquisition introduces vertical industry agent cloning technology and an AI visualization engine, filling a critical strategic gap in building BGM's multi-agentic production platform.
Financial impact: All-stock transaction settled by issuing 16,663,427 Class A ordinary shares at $2.50 per share, expanding BGM's AI application portfolio and market resources.
To acquire 100% of the equity interests of Wonder Dragon, which possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory. This acquisition supports BGM's 'medicine + tea + health' product ecosystem and provides a solid foundation for R&D in medicinal tea applications.
Financial impact: All-stock transaction valued at RMB 550 million (approx. $76 million USD), settled by issuing 38,165,290 Class A ordinary shares at $2.00 per share.
To officially enter the domains of AI intelligent technology and financial/insurance services. The acquisition brought AIX's subsidiaries, including RONS Intelligent Technology and Shenzhen Xinbao Investment Management, under BGM's umbrella, enabling the integration of intelligent technology with biopharmaceuticals.
Financial impact: AIX exchanged its Duxiaobao AI insurance platform and data for 72% of BGM Group's shares, making AIX the majority shareholder. The core assets were valued at $140 million.
Strategic Partnerships
Deepening cooperation to enhance the distribution of biopharmaceutical products, optimize supply chain logistics, and leverage Jointown's extensive network in the Chinese healthcare market.
Terms: Specific financial terms were not publicly disclosed.